Feed KALA
KA
Kala Pharmaceuticals, Inc. KALA NASDAQ · Healthcare · United States
$0.14 -13.79% -$0.02
Summary
37 / 100 · Bulios Score
Valuation 100Growth 0Profitability -Quality 0Debt 69Stability 19
What speaks for it
- It has no debt and holds $229.0K in cash.
What to watch
- It passes only 3 of the 9 points of the Piotroski financial health test.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
It is shrinkingRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $10.1M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $7.23M
Debt $0.00
Free cash flow over 12 months -$19.9M
It has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 6
- Sell 1
Today's price within the analysts' price targets
Today's price $0.14 Average target $18.25
$0.14 $35
The average target of $18.25 is 13,048% above today's price. 36% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.